Seaport Therapeutics Shares Surge 17% Following Upsized IPO

Seaport Therapeutics Inc. made a robust entry into the public markets, with its stock price surging 17% during its first day of trading. The positive price action indicates strong initial investor confidence in the company's valuation and future prospects. The rally follows a successful capital raise in which the company expanded the size of its initial public offering. By upsizing the IPO, Seaport was able to capitalize on significant demand from institutional and retail investors. In total, the drugmaker secured nearly $255 million in proceeds from the offering. These funds are expected to support the company's ongoing research and development efforts as it advances its therapeutic pipeline. While the debut is a positive signal for the company, it also reflects a broader appetite for biotech listings in the current market environment. Traders will now look to see if the company can maintain this momentum as it transitions into its first full quarter as a public entity.